A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/brad-friedman

Paste this link in an email to share.

Ok

Scientists / Our Scientists

Brad Friedman

Principal Scientist, Bioinformatics & Computational Biology

Postdoc Mentor

"Genomics brings new insights to neurodegenerative disease."

Years at Genentech

Publications

Awards & Honors

I joined Genentech in 2011 and led the development of software infrastructure which continues to underlie much of our company’s gene expression research. In 2014 I began collaborating with the Neuroscience department to study the role of non-neuronal cells (“glia”) in neurodegenerative diseases, with a particular emphasis on Alzheimer’s and Parkinson’s diseases. We combine human genetics, gene expression and other types of data to identify and understand novel therapeutic targets and biomarkers.

At Genentech I have access to both industry-leading databases and information systems as well as world-class neuroscientists with whom I collaborate to develop and test hypotheses emerging from these data. This highly collaborative research environment is an exciting place to do science.

Featured Publication

Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer0s Disease Not Evident in Mouse Models.

Cell Rep. 2018 Jan 16;22(3):832-847.

Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, Modrusan Z, Larson JL, Kaminker JS, van der Brug MP, Hansen DV.

View Abstract

Human genetics and neuropathology point to a role for glial cells in the development of Alzheimer’s and other neurodegenerative diseases. Microglia in particular are thought to have both “good” aspects, such phagocytosis of lipids, protein aggregates and apoptotic cells, and “bad” aspects, such as secretion of toxic inflammatory factors, actively spreading prion-like protein species, or aberrant engulfment of not-yet-dead synapses or neurons. I combine human genetics and gene expression to understand which of these pathways are most important for disease progression, and which might be amenable to therapeutic intervention.

Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology

Neuron, ISSN: 10974199 08966273

Seung-Hye Lee; Bill Meilandt; Luke Xie; Vineela Gandham; Hai Ngu; Kai Barck; Mitchell G. Rezzonico; Jose Imperio; Guita Lalehzadeh; Melanie Huntley; Kimberly Stark; Oded Foreman; Rick Carano; Brad A. Friedman; Morgan Sheng; Amy Easton; Christopher J. Bohlen; David Hansen

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

A link to this page has been copied to your clipboard.

Brad Friedman

Principal Scientist, Bioinformatics & Computational Biology

Featured Publication

Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer0s Disease Not Evident in Mouse Models.